33 completed, 3 terminated, 1 active not recruiting, 1 unknown. 39 Phase 2, 7 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 39 | Completed 33, Terminated 3, Active not recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 7 | Completed 6, Active not recruiting 1 |
| Phase 3 | 3 | Completed 1, Unknown 1, Withdrawn 1 |
Follow Open-angle Glaucoma: new trials by email Literature Review of Open-angle Glaucoma trials Research Report on Open-angle Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of PER-001 in Participants With Open-Angle Glaucoma PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham - Open-angle Glaucoma | Phase 1 / Phase 2 | Completed | Perfuse Therapeutics, Inc. | 33 | 2023-05-25 | 2026-06-05 |
| Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension Nebivolol Ophthalmic Suspension 1 Percent, Nebivolol Ophthalmic Suspension 0.5 Percent, Timolol Ophthalmic Suspension 0.5 Percent - Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Betaliq, Inc. | 226 | 2021-04-15 | 2024-04-17 |
| AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension AGN-193408 SR, Lumigan, Sham Administration - Open-angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Active not recruiting | AbbVie | 100 | 2020-11-16 | 2026-05-22 |
| A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension Fixed Combination, Bimatoprost, Timolol - Open-Angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Completed | ForSight Vision5, Inc. | 55 | 2016-04-30 | 2019-02-25 |
| A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma MGV354 ophthalmic suspension, MGV354 placebo - Ocular Hypertension, Open-Angle Glaucoma | Phase 1 / Phase 2 | Completed | Alcon Research | 191 | 2016-03-02 | 2018-07-02 |
| Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension DE-117 Low Dose ophthalmic solution, DE-117 Low/Middle Dose ophthalmic solution, DE-117 Middle Dose ophthalmic solution - Open-angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Santen Inc. | 184 | 2014-06-01 | 2018-04-18 |
| A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma Latanoprost Punctal Plug Delivery System (L-PPDS) - Ocular Hypertension, Open-Angle Glaucoma | Phase 2 | Completed | Mati Therapeutics Inc. | 86 | 2013-12-01 | 2017-01-18 |
| A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months AR-12286 Ophthalmic Solution 0.7%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5% - Ocular Hypertension, Open-angle Glaucoma | Phase 2 | Completed | Aerie Pharmaceuticals | 211 | 2012-10-01 | 2023-08-22 |
| A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2% Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, Brimonidine tartrate ophthalmic solution, 0.2% - Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Alcon Research | 103 | 2011-09-01 | 2013-07-08 |
| Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412C AL-59412C injectable solution, Travoprost injectable solution, AL-59412C Vehicle - Open-angle Glaucoma, Ocular Hypertension | Phase 2 | Terminated | Alcon Research | 4 | 2011-06-01 | 2013-10-25 |
| Divided Dose of TRAVATAN® Travoprost Ophthalmic Solution, 0.00013%, Travoprost Ophthalmic Solution, 0.00033%, Travoprost Ophthalmic Solution, 0.001% - Open-angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Alcon Research | 67 | 2011-02-01 | 2017-05-05 |
| Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension DE-112, DE-112 Vehicle Solution, Timolol Maleate Solution - Open-angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Completed | Santen Inc. | 147 | 2011-01-01 | 2012-12-17 |
| Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2 - Open-Angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Completed | Allergan | 109 | 2010-09-23 | 2020-03-30 |
| A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG Latanoprost Punctal Plug Delivery System, Xalatan - Ocular Hypertension, Open-Angle Glaucoma | Phase 2 | Completed | Mati Therapeutics Inc. | 15 | 2009-12-01 | 2014-01-10 |
| Safety and Efficacy of a Drug Delivery System in Glaucoma High Dose Drug Device, Low Dose Drug Device, Placebo Device - Open-angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Vistakon Pharmaceuticals | 47 | 2009-10-01 | 2015-03-06 |
| Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, Brimonidine tartrate ophthalmic solution, 0.2% - Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Terminated | Alcon Research | 195 | 2009-10-01 | 2013-07-04 |
| Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension AL-39256 Ophthalmic Suspension, 1%, Latanoprost Ophthalmic Solution, 0.005%, Vehicle - Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Alcon Research | 104 | 2009-07-01 | 2014-07-15 |
| Goniocurettage as First Choice of Surgical Treatment in Chronic Open-Angle Glaucoma: Outcomes and Complications Goniocurettage - Open-Angle Glaucoma, Surgery | Phase 2 / Phase 3 | Unknown | Federal University of Minas Gerais | 32 | 2009-06-01 | 2012-01-18 |
| Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension DE-104 medium concentration, DE-104 high concentration, Placebo - Open-Angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Completed | Santen Inc. | 49 | 2009-03-01 | 2011-11-03 |
| A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS) Latanoprost - Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Mati Therapeutics Inc. | 32 | 2009-01-01 | 2013-09-19 |
Showing 20 of 39. Sign in to see all of them.
Glaucoma, Open-Angle (39) · Ocular Hypertension (32) · Glaucoma (10) · Hypertension (4)
Eye Diseases (39) · Glaucoma (29) · Ocular Hypertension (7) · Cardiovascular Diseases (4) · Vascular Diseases (4)
Latanoprost (10) · anecortave acetate (5) · Travoprost (4) · brinzolamide (4) · Bimatoprost (3) · Brimonidine Tartrate (2) · Ophthalmic Solutions (2) · Timolol (2) · AL-12182 (1)
Alcon Research (22) · Santen Inc. (4) · Mati Therapeutics Inc. (3) · Santen Pharmaceutical Co., Ltd. (2) · AbbVie (1) · Aerie Pharmaceuticals (1) · Allergan (1) · Betaliq, Inc. (1) · Federal University of Minas Gerais (1) · ForSight Vision5, Inc. (1) · Perfuse Therapeutics, Inc. (1) · Vistakon Pharmaceuticals (1)
United States (24) · Japan (3) · Brazil (2) · Australia (1) · Belgium (1) · Canada (1) · Germany (1) · Israel (1) · Panama (1) · Philippines (1) · Singapore (1) · Spain (1)
Theresa Landry (4) · Oscar Cuzanni, MD, MSc (2) · Theresa Landry, Ph.D. (2) · Theresa Landry, PhD (2) · Brian Levy, OD (1) · James Teague, BS, Sr. Clinical Manager (1) · Julia White (1) · Kristin Peterson (1) · Matt Walker, PhD (1) · Michelle Chen, PhD (1) · Phillip Lai, MD (1) · Ravaughn Williams, OD, MS (1)